Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Navnita Dutta"'
Autor:
Sikander Ailawadhi, Meghna Ailawadhi, Navnita Dutta, Ricardo D. Parrondo, Vivek Roy, Taimur Sher, Mizba Baksh, Ahsan Rasheed, Saurav Das, Andre J. Fernandez, Aneel Paulus, Asher A. Chanan‐Khan
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 19013-19020 (2023)
Abstract Introduction Health information technology (HIT) has the potential to improve healthcare delivery and engagement. Studying racial‐ethnic disparities in HIT engagement will help understand and overcome challenges to healthcare utilization.
Externí odkaz:
https://doaj.org/article/1a893cfa3efb441eb05f8da1cd56f354
Autor:
Yan Luo, Matthew S Block, Barath Shreeder, James W Jenkins, Huashan Shi, Purushottam Lamichhane, Kexun Zhou, Deborah A Bahr, Sophia Kurian, Katherine A Jones, Joshua I Daum, Navnita Dutta, Brian M Necela, Martin J Cannon, Keith L Knutson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background Ovarian cancer (OC), a highly lethal cancer in women, has a 48% 5-year overall survival rate. Prior studies link the presence of IL-17 and Th17 T cells in the tumor microenvironment to improved survival in OC patients. To determine if Th17
Externí odkaz:
https://doaj.org/article/c7f089de207141e2ac20f5bd2a7c68ba
Autor:
Yifan Zhai, Asher Chanan-Khan, Shaomeng Wang, Dajun Yang, Sikander Ailawadhi, Anthony Letai, Jeremy Ryan, Caixia Li, Depei Wu, Jeanne A. Stuckey, Chao-Yie Yang, Sally Przybranowski, Donna McEachern, Mi Wang, Liu Liu, Longchuan Bai, Bing Han, James Miller, John A. Copland, Gina Ciccio, Nabanita Halder, Navnita Dutta, Yan Yin, Ping Min, Jianyong Chen, Saijie Zhu, Hengbang Wang, Guangfeng Wang, Alak Manna, Douglas D. Fang, Aneel Paulus, Jing Deng
Supplementary Tables from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93cc29265231a5604031f426cd989d83
https://doi.org/10.1158/1078-0432.22489368.v1
https://doi.org/10.1158/1078-0432.22489368.v1
Autor:
Yifan Zhai, Asher Chanan-Khan, Shaomeng Wang, Dajun Yang, Sikander Ailawadhi, Anthony Letai, Jeremy Ryan, Caixia Li, Depei Wu, Jeanne A. Stuckey, Chao-Yie Yang, Sally Przybranowski, Donna McEachern, Mi Wang, Liu Liu, Longchuan Bai, Bing Han, James Miller, John A. Copland, Gina Ciccio, Nabanita Halder, Navnita Dutta, Yan Yin, Ping Min, Jianyong Chen, Saijie Zhu, Hengbang Wang, Guangfeng Wang, Alak Manna, Douglas D. Fang, Aneel Paulus, Jing Deng
Supplementary Figures from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee10d364e50997d25d9fc8b6127afe2e
https://doi.org/10.1158/1078-0432.22489371.v1
https://doi.org/10.1158/1078-0432.22489371.v1
Autor:
Jing Deng, Aneel Paulus, Douglas D. Fang, Alak Manna, Guangfeng Wang, Hengbang Wang, Saijie Zhu, Jianyong Chen, Ping Min, Yan Yin, Navnita Dutta, Nabanita Halder, Gina Ciccio, John A. Copland, James Miller, Bing Han, Longchuan Bai, Liu Liu, Mi Wang, Donna McEachern, Sally Przybranowski, Chao-Yie Yang, Jeanne A. Stuckey, Depei Wu, Caixia Li, Jeremy Ryan, Anthony Letai, Sikander Ailawadhi, Dajun Yang, Shaomeng Wang, Asher Chanan-Khan, Yifan Zhai
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research.
Purpose: Development of B-cell lymphoma 2 (BCL-2)–specific inhibitors poses unique challenges in drug design because of BCL-2 homology domain 3 (BH3) shared homology between BCL-2 family members and the shallow surface of their protein–protein in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::068284dbdeaaa9280e60219d582ece2e
https://pubmed.ncbi.nlm.nih.gov/36048524
https://pubmed.ncbi.nlm.nih.gov/36048524
Autor:
Mizba Baksh, Aneel Paulus, Meghna Ailawadhi, Vivek Roy, Navnita Dutta, Gerson Quintero, Asher Chanan-Khan, Chander Shekher Aggarwal, Vivek Kumar, Mays F Abdulazeez, Victoria R. Alegria, Sikander Ailawadhi, Taimur Sher
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e449-e455
Despite significant improvements in multiple myeloma (MM) treatment modalities, patient mortality early in the course of disease has been identified as a persistent phenomenon with variable reported rates and causes. Trends in early mortality over ti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad29845f5075f4cb20df5c037de9cf68
https://doi.org/10.1016/j.clml.2020.12.023
https://doi.org/10.1016/j.clml.2020.12.023
Autor:
Sikander Ailawadhi, Ricardo D. Parrondo, Navnita Dutta, Bing Han, Gina Ciccio, Yesesri Cherukuri, Victoria R. Alegria, Betsy R. LaPlant, Vivek Roy, Taimur Sher, Brett Edwards, Stephanie Lanier, Alak Manna, Keisha Heslop, Thomas Caulfield, Emir Maldosevic, Peter Storz, Rami Manochakian, Yan Asmann, Asher A. Chanan-Khan, Aneel Paulus
Publikováno v:
Cancers; Volume 15; Issue 2; Pages: 477
Bcl-2 and Mcl-1 proteins play a role in multiple myeloma (MM) cell survival, for which targeted inhibitors are being developed. AT-101 is an oral drug, which disrupts Bcl-2 and Mcl-1 function, impedes mitochondrial bioenergetic processes and induces
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19a51d9212186919cd032c3a306a0fcd
https://doi.org/10.3390/cancers15020477
https://doi.org/10.3390/cancers15020477
Autor:
Pirouz M Daftarian, Nadine Nadine, Orkash Hushur, Roxana Dronca, Navnita Dutta, Keith L Knutson
Publikováno v:
The Journal of Immunology. 208:66.14-66.14
Markers of immune related adverse events and response in patients treated with immune checkpoint inhibitors (ICI) may shed light into ICI resistance, T cell exhaustion and other combinatorial therapies. The elevated levels of these biomarkers have po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c3299aecae154ca9fe3b5b1a5d76c26
https://doi.org/10.4049/jimmunol.208.supp.66.14
https://doi.org/10.4049/jimmunol.208.supp.66.14
Autor:
Asher Chanan-Khan, Eduardo N. Chini, Fabio Malavasi, Keith L. Knutson, Javier Pinilla-Ibarz, Taimur Sher, Sonikpreet Aulakh, Nicole Lamanna, Aneel Paulus, Alak Manna, Sikander Ailawadhi, Laura J. Lewis-Tuffin, Rami Manochakian, Timothy Kellett, Navnita Dutta
Publikováno v:
Blood Adv
Patients with chronic lymphocytic leukemia (CLL) are characterized by monoclonal expansion of CD5+CD23+CD27+CD19+κ/λ+ B lymphocytes and are clinically noted to have profound immune suppression. In these patients, it has been recently shown that a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::671d714489fb541262d7c8a3a1048e86
https://europepmc.org/articles/PMC7252547/
https://europepmc.org/articles/PMC7252547/
Autor:
Geraldine Raja, Keith L. Knutson, Yan Luo, Martin J. Cannon, Navnita Dutta, Deborah Bahr, Shreeder Barath
Publikováno v:
Cancer Research. 79:1464-1464
Dendritic cells (DCs) are the most potent antigen-presenting cells which bridges innate and adaptive immunity, but how DC-derived signals regulate and induce T cell lineage choices remains unclear. The p38 MAPK pathway plays an essential role in regu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7443a0c09099ebce2d8ae0cfa3bb1ce
https://doi.org/10.1158/1538-7445.am2019-1464
https://doi.org/10.1158/1538-7445.am2019-1464